Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Continuation Study of TAK-755 in Severe Congenital TTP
2024-513839-24-00Phase 3Completed
- Sponsor
- Baxalta
- Start
- Sep 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of Apadamtase alfa in Upshaw-Schulman syndrome (USS), sponsored by Baxalta. Primary endpoint: Long-term safety of TAK-755. Started Sep 2021; status: completed.
02
Drugs
Apadamtase alfa
03
Conditions
Upshaw-Schulman syndrome (USS)
Beyond the preview
Go deeper on 2024-513839-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513839-24-00.